SCHEMBL26019671

SCHEMBL26019671

Cc1cc(Cl)ccc1C(=O)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 2/20 0.47
FLT4 P35916 2/20 0.47
KDR P35968 2/20 0.47
CYP11B2 P19099 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TSHR P16473 2/20 0.42
CASP1 P29466 1/20 0.42
MYC P01106 1/20 0.41
HTT P42858 2/20 0.41
SERPINE1 P05121 1/20 0.41
LMNA P02545 1/20 0.41
KCNH2 Q12809 1/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14310501 0.83 FLT1 (0.46) FLT1FLT4KDRCYP11B2SMN1; SMN2
SCHEMBL12532565 0.82 SMN1; SMN2 (0.59) FLT1FLT4KDRNR1H4SMN1; SMN2
SCHEMBL107882 0.82 FLT1 (0.51) FLT1FLT4KDRCYP11B2SMN1; SMN2
SCHEMBL11988898 0.80 NFE2L2 (0.45) FLT1FLT4KDRSMN1; SMN2NPC1
SCHEMBL250256 0.79 FLT1 (0.53) FLT1FLT4KDRCYP11B2SMN1; SMN2
SCHEMBL10917039 0.79 ABL1 (0.59) FLT1FLT4KDRSMN1; SMN2RAB9A
SCHEMBL13900904 0.79 CYP11B2 (0.45) FLT1FLT4KDRCYP11B2SMN1; SMN2
SCHEMBL11988942 0.78 ESRRB (0.49) SMN1; SMN2NPC1RAB9ATSHRHTT
SCHEMBL28019535 0.78 KDM4E (0.53) SMN1; SMN2RAB9ATSHRCASP1MYC
SCHEMBL109654 0.78 SMN1; SMN2 (0.63) FLT1FLT4KDRSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257382-A1 HETEROCYCLIC COMPOUND AND USE THEREOF WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2023-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257382-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TRPC5, TRPC1, GOT1 FLT1 4461/4885FLT4 4610/4885KDR 4104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.